Skip to main content

This podcast discusses the effect of cirrhosis on pregnancy. While women that have cirrhosis get pregnant less often, when women with cirrhosis do become pregnanct, there are added concerns and dangers. Complications include and increased risk of bleeding esophageal varicies, worsening hepatic function, internal bleeding, and hepatic encephalopathy.

Details from the article are posted below.

Esophageal Varicies

Esophageal variceal bleeding has been reported in 18% to 32% of pregnant women with cirrhosis and in up to 50% of those with known portal hypertension.  Among those with preexisting varices, up to 78% will have gastrointestinal bleeding during pregnancy, with a mortality rate of 18% to 50%.  In contrast, pregnant patients with noncirrhotic portal hypertension fare much better. Their mortality rate from variceal bleeding is between 2% to 6%] This disparity may be related to the severity of their underlying liver disease, with patients with cirrhosis more likely to be coagulopathic.

Variceal bleeding most commonly occurs during the second and third trimesters when maternal blood volume is maximally expanded and the larger fetus causes increased compression of the inferior vena cava and collateral vasculature.

As in nonpregnant patients with cirrhosis, endoscopic band ligation remains the mainstay of therapy for acute episodes of hemorrhage. The first case of successful band ligation in a pregnant patient with acute bleeding was reported in 1998 by Starkel et al., but no prospective randomized trials for this treatment currently exist. As in the nongravid population, sclerotherapy was previously looked to as a potential alternative, but it has largely been replaced by band ligation. Experts argue that band ligation should be preferred during pregnancy because it avoids any potential risk from chemical instillation.

Upper endoscopy in general appears to be safe during pregnancy, with the main risk being fetal hypoxia from sedative drugs or positioning. No cases of premature labor or fetal malformations have been reported in patients who have undergone endoscopy during pregnancy.

Octreotide, designated as pregnancy category B by the Food and Drug Administration, is often used to treat acute variceal bleeding, although its safety has not been well studied in pregnant patients. Given its similarity to vasopressin, however, possible concerns include arteriolar vasospasm, which can result in decreased placental perfusion and an increased risk of placental abruption, myocardial infarction, peripheral ischemia, and hypertension.

Hepatic Decompensation

Up to 24% of pregnant patients with cirrhosis will also experience hepatic decompensation, which can lead to rapid clinical deterioration. This has been described in all stages of pregnancy, but often occurs after episodes of variceal bleeding.

When fulminant hepatic failure occurs, the only treatment available may be emergent liver transplantation. This has been performed during pregnancy in a small number of cases, with successful outcomes for both mother and fetus. Reported complications remain high, however, and have included an increased risk of fetal ischemia, pregnancy-induced hypertension, anemia, caesarian section, and preterm delivery. Moreover, these case reports largely involved women without underlying cirrhosis, and it is unclear how underlying liver disease would change the outcome.





Obesity and Fatty Liver Disease

Obesity, and all of its related complications, is more serious than most adults in America believe. More than one-third (34.9% or 78.6 million) of U.S. adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancer, are some of the leading causes of preventable death. We are seeing an increase in the number of young children and adolescents developing obesity, and all of the related complications.

The cost of obesity is staggering, with annual medical cost of obesity exceeding $147 billion in 2008 U.S. dollars. The medical costs for people who are obese were $1,429 higher than those of normal weight.

Dr. Galati and the Liver Specialists of Texas team are dedicated to evaluate, treat, and manage all aspects of obesity and non-alcoholic fatty liver disease (NAFLD and NASH), including the complication of cirrhosis and liver failure. Developing a customized plan of care for each patient they see is their objective.

Liver Transplant Resources

Dr. Galati has been involved in Liver Transplantation since 1989. As Medical Director for the Center for Liver Disease and Transplantation at Houston Methodist Hospital, Dr. Galati has cared for thousands of patients with advanced liver disease. In those with the most severe form of advanced liver disease and cirrhosis, liver transplantation is a life-saving surgery. For more information on liver transplantation, click here.

Indications for liver transplant include:

Online LIVER Second Opinion

  • 1

    From the comfort of your home, without the need to spend additional money on travel, lodging, and food, receive and expert second opinion from the expert physicians at Liver Specialists of Texas

  • 2

    There are five steps in the process of requesting a second opinion. We anticipate the steps will take you about 30-65 minutes to complete.

  • 3

    Have your medical records or those of your loved one on hand as you fill out the medical history questionnaire portion of the online process. The medical history questionnaire is detailed so having medical records to quickly reference will help make the process more efficient.

  • 4

    To start the process of an Online Liver Second Opinion, please fill out the initial contact form and fax back to our office. A representative from our office will call you for additional details.